HRT: A Complete Evidence-Based Guide to Hormone Replacement Therapy

Hormone replacement therapy (HRT), also called menopausal hormone therapy (MHT), replaces the estrogen your ovaries stop making at menopause, plus a progestogen if you still have a uterus, and it is the most effective treatment for hot flashes and night sweats, cutting their frequency by about 75% in a Cochrane review (Maclennan et al., 2004). According to the 2022 hormone therapy position statement of The North American Menopause Society, now The Menopause Society, the benefits outweigh the risks for most healthy women who start before age 60 or within 10 years of their last period.

What Is Hormone Replacement Therapy?

Hormone replacement therapy, commonly called HRT or menopausal hormone therapy (MHT), involves supplementing the hormones your ovaries gradually stop producing as you approach and pass through menopause. The primary hormones involved are estrogen and progesterone, though testosterone is increasingly part of the conversation.

During perimenopause, which can begin in your early 40s, hormone levels start to fluctuate unpredictably. By the time you reach menopause (defined as 12 consecutive months without a period, at an average age of 51), estrogen production has dropped significantly. This decline drives the symptoms most women associate with menopause: hot flashes, night sweats, sleep disruption, vaginal dryness, mood changes, and brain fog (Santoro et al., 2015).

HRT works by restoring hormone levels to a range that alleviates these symptoms. It does not aim to replicate the hormone levels of your 20s. Rather, it provides enough hormonal support to protect your tissues, bones, and cardiovascular system during a vulnerable transition.

HRT, MHT, HT and BHRT: what the names mean

HRT, menopausal hormone therapy (MHT) and hormone therapy (HT) all describe the same prescription treatment. Estrogen replacement therapy (ERT) is an older name for estrogen-only therapy. Bioidentical hormone replacement therapy (BHRT) usually refers to custom compounded hormones, which are covered in the bioidentical section below.

US medical societies, including The Menopause Society, the American College of Obstetricians and Gynecologists (ACOG) and the Endocrine Society, now prefer "hormone therapy" because the goal is symptom relief and tissue protection, not restoring premenopausal levels. Hormone therapy is also used in gender-affirming care and for testosterone replacement therapy (TRT) in men, but these sections focus on menopause.

Types of HRT

Estrogen-Only Therapy (ET)

Estrogen-only HRT is prescribed for women who have had a hysterectomy. Without a uterus, there is no risk of endometrial cancer from unopposed estrogen, so progesterone is unnecessary. Estrogen-only therapy has the most favorable risk profile of all HRT types and was associated with a slight decrease in breast cancer risk in the Women’s Health Initiative (WHI) trial (WHI Steering Committee, 2006).

Combined Estrogen-Progesterone Therapy (EPT)

If you still have your uterus, you need progesterone (or a progestogen) alongside estrogen. Estrogen alone stimulates the uterine lining, which can lead to endometrial hyperplasia and cancer over time. Progesterone counteracts this effect. Combined therapy can be given cyclically (progesterone for 10 to 14 days per month, producing a withdrawal bleed) or continuously (daily progesterone with no bleed) (The NAMS 2017 Hormone Therapy Position Statement).

Cyclic regimens tend to suit women in perimenopause or within a year or two of their last period, when continuous progestogen often causes unpredictable spotting. Continuous combined regimens are more common later, once bleeding has settled.

Delivery Methods

How you take HRT matters, sometimes as much as what you take. Here are the main options:

• Transdermal patches: Applied to the skin once or twice weekly. Patches bypass the liver entirely, which means they do not increase clotting risk. This is widely considered the safest delivery route for estrogen (Mohammed et al., 2015).
• Topical gels and creams: Applied daily to the skin. Like patches, these are transdermal and carry a lower clot risk than oral formulations.
• Oral pills: Taken daily. Convenient, but oral estrogen passes through the liver (first-pass metabolism), which increases production of clotting factors and certain inflammatory markers.
• Vaginal estrogen: Low-dose creams, rings, or tablets applied locally. These treat vaginal and urinary symptoms with minimal systemic absorption. Most guidelines consider vaginal estrogen safe even for women with contraindications to systemic HRT (The NAMS, 2020).
• Subcutaneous pellets: Small pellets inserted under the skin every 3 to 6 months. They provide steady hormone levels but are harder to adjust or remove if problems arise. Pellets are not FDA-approved and are typically compounded.
• Injections: Intramuscular injections of estrogen (estradiol valerate or cypionate) given every 1 to 2 weeks. Less commonly used for menopause; more common in transgender hormone therapy.

Which HRT delivery method is best?

Transdermal estradiol is the delivery method most menopause specialists start with, because a meta-analysis found that oral estrogen raised the risk of venous blood clots while transdermal estrogen did not (Mohammed et al., J Clin Endocrinol Metab, 2015). Oral tablets remain a reasonable choice for women without clot risk factors. The table compares the options described above.

Progesterone Options

For the progesterone component, you have two broad categories:

• Micronized progesterone (Prometrium): Chemically identical to the progesterone your body makes. Generally better tolerated, with a more favorable effect on lipids, mood, and sleep. The French E3N cohort study suggests micronized progesterone may carry less breast cancer risk than synthetic progestins (Fournier et al., 2008).
• Synthetic progestins (medroxyprogesterone acetate, norethindrone): These are not identical to your body’s progesterone. Medroxyprogesterone acetate (MPA), used in the WHI, has been linked to a higher breast cancer risk compared to micronized progesterone.
• Levonorgestrel IUD (Mirena): Increasingly used off-label to provide endometrial protection while delivering progesterone locally to the uterus, minimizing systemic side effects.

Bioidentical vs. Synthetic: What the Evidence Actually Shows

The term “bioidentical” refers to hormones that are chemically identical to those your body produces. Estradiol, estriol, progesterone, testosterone, and DHEA are all bioidentical hormones. Many FDA-approved products contain bioidentical hormones. The estradiol in your patch and the micronized progesterone in your Prometrium capsule are bioidentical.

The confusion arises because the term has been co-opted by compounding pharmacies and some practitioners to market custom-mixed hormone preparations. These compounded “bioidentical hormone replacement therapy” (BHRT) products are not FDA-regulated, meaning they have not undergone the same rigorous testing for safety, efficacy, potency, and purity (ACOG Committee Opinion, 2019).

There are legitimate reasons to use compounded hormones. Some women need doses or combinations not commercially available, or they have allergies to inactive ingredients in standard products. But the marketing claim that compounded BHRT is inherently safer than FDA-approved HRT is not supported by evidence. Both the Endocrine Society and ACOG recommend FDA-approved bioidentical hormones as first-line therapy when possible.

Salivary hormone testing, often promoted by BHRT practitioners, is not reliable for monitoring or dosing HRT. Serum (blood) testing is the standard (Endocrine Society, 2016).

Is compounded BHRT the same as FDA-approved bioidentical HRT?

Compounded BHRT and FDA-approved bioidentical HRT can contain the same molecules, estradiol and progesterone, but only the FDA-approved products are tested batch by batch for dose and purity. Compounded creams, troches and pellets are made by a pharmacy for one patient and carry no FDA label. The bioidentical hormone therapy explainer covers when compounding is reasonable and what to ask the pharmacy.

Who Needs HRT?

HRT is not a blanket recommendation for every woman entering menopause. But for several groups, the evidence strongly favors treatment:

• Women with moderate to severe vasomotor symptoms: If hot flashes and night sweats are disrupting your sleep, work, or quality of life, HRT is the most effective treatment available. It reduces hot flash frequency by roughly 75% (Maclennan et al., 2004).
• Premature ovarian insufficiency (POI): Women who stop menstruating before age 40. Without hormone replacement, these women face elevated risks of osteoporosis, cardiovascular disease, cognitive decline, and early death. HRT is considered medically necessary, not optional, for this group (Webber et al., 2016).
• Surgical menopause: Women who have had their ovaries removed experience an abrupt, complete loss of hormones. The symptom burden is often severe, and early HRT is strongly recommended.
• Genitourinary syndrome of menopause (GSM): Vaginal dryness, painful intercourse, recurrent UTIs, and urinary urgency. Low-dose vaginal estrogen is first-line treatment and is effective for the vast majority of women.
• Women at high risk of osteoporosis: HRT is the only menopause treatment that both relieves symptoms and protects bone density. It reduces hip fractures by 34% according to WHI data.

Each of these groups has its own reading on the site. Surgical menopause after oophorectomy brings the most abrupt symptoms, and genitourinary syndrome, also called atrophic vaginitis, often responds to vaginal estrogen alone. The menopause condition overview lists the full range of symptoms that bring women to treatment.

Who Should Not Take HRT?

Systemic HRT is generally not prescribed for women with a history of breast cancer or another estrogen-sensitive cancer, unexplained vaginal bleeding, a previous blood clot, stroke or heart attack, active liver disease, or known coronary heart disease. These contraindications appear in FDA labeling for estrogen products and are reflected in the Menopause Society 2022 position statement.

Several conditions call for extra care rather than a flat no. Women with migraine with aura, obesity, high triglycerides, gallbladder disease or a family history of clots are usually steered toward transdermal estrogen at the lowest effective dose. Women carrying a BRCA1 or BRCA2 variant who have had preventive ovary removal are a separate group, and many specialists support HRT for them until the average age of menopause.

Low-dose vaginal estrogen is the main exception. Because so little reaches the bloodstream, it is often used for vaginal dryness even in women who cannot take systemic HRT, ideally after a conversation with their oncologist. Any bleeding after menopause should be checked before starting treatment; the postmenopausal bleeding page explains the usual workup.

Can You Start HRT During Perimenopause?

Yes, HRT can be started during perimenopause, the years of irregular cycles before the final period, and many women begin there because hot flashes, poor sleep and mood changes often peak before periods stop. A diagnosis is based on age and symptoms. Blood tests for FSH are usually unnecessary in women over 45 because levels swing from week to week.

Perimenopausal women who still ovulate may need contraception as well as symptom relief. A levonorgestrel IUD combined with transdermal estradiol covers both needs for many women, while cyclic progesterone keeps bleeding more predictable. The perimenopause guide walks through the stages and early symptoms in more detail.

Benefits of HRT

Symptom Relief

This is the primary reason most women start HRT, and it is remarkably effective. Hot flashes, night sweats, sleep disruption, vaginal dryness, and mood instability all respond well to appropriate hormone therapy. For many women, the improvement in quality of life is dramatic.

Bone Protection

Estrogen is critical for maintaining bone density. After menopause, women can lose up to 20% of their bone density within 5 to 7 years. HRT halts this loss and reduces fracture risk at the hip, spine, and other sites. This benefit is maintained for as long as therapy continues (Rossouw et al., 2002; WHI).

Cardiovascular Protection: The Timing Hypothesis

This is where the story gets nuanced. The WHI initially suggested HRT increased heart disease risk. But subsequent reanalysis revealed a critical detail: age and timing matter enormously.

Women who started HRT within 10 years of menopause or before age 60 showed a trend toward reduced cardiovascular events. Women who started HRT more than 10 to 20 years after menopause, when atherosclerosis may already be established, showed increased risk. This is known as the “timing hypothesis” or “window of opportunity,” and it has been supported by multiple subsequent analyses and the ELITE trial (Hodis et al., 2016).

The WHI age analysis by Rossouw and colleagues in JAMA (Rossouw et al., 2007) first showed this pattern by years since menopause. The ELITE trial, published in the New England Journal of Medicine, then found that oral estradiol slowed carotid artery thickening in women within 6 years of menopause but not in women 10 or more years past it (Hodis et al., NEJM, 2016). HRT is still not prescribed to prevent heart disease on its own.

Transdermal estrogen, which avoids liver first-pass effects, appears to have the most favorable cardiovascular profile. The Danish Osteoporosis Prevention Study (DOPS), which followed women for over 16 years, found that those randomized to HRT early in menopause had significantly reduced risk of heart failure, heart attack, and death without any increased cancer risk (Schierbeck et al., 2012).

Cognitive Benefits

Observational data suggest that HRT started early in menopause may protect against cognitive decline and possibly reduce Alzheimer’s risk. The WHIMS (WHI Memory Study) found increased dementia risk, but that study enrolled women aged 65 to 79, well past the proposed window of benefit. Research on early initiation, including the KEEPS-Cog and ELITE trials, has been more encouraging, though definitive evidence is still emerging (Henderson & Brinton, 2021).

KEEPS-Cog and the cognitive arm of ELITE found that HRT started early neither helped nor harmed memory and thinking over several years. That supports safety for the brain when HRT is started early, but it is not evidence that HRT prevents dementia. Menopause-related brain fog during menopause often eases as sleep and hot flashes improve.

Other Benefits

HRT has been associated with reduced risk of type 2 diabetes, improved joint health, better skin elasticity and wound healing, and reduced risk of colon cancer (in the WHI combined therapy arm). Some women also report improvements in energy, libido, and overall well-being.

Risks and the WHI Controversy

The Study That Changed Everything

In 2002, the WHI estrogen-plus-progestin trial was halted early after finding increased rates of breast cancer, heart disease, stroke, and blood clots. Headlines were alarming. Millions of women abruptly stopped HRT, and prescriptions dropped by over 50% worldwide.

But the story was more complicated than the headlines suggested. The average age of WHI participants was 63, more than a decade past menopause. The formulation used was oral conjugated equine estrogen (Premarin) plus medroxyprogesterone acetate (Provera), a specific combination that may not reflect modern HRT practice. The absolute risk increases were small: roughly 8 additional breast cancers per 10,000 women per year (Writing Group for the WHI, 2002).

The estrogen-only arm of the WHI, reported in JAMA in 2004, told a different story: women without a uterus who took conjugated estrogen alone had no increase in breast cancer (Anderson et al., 2004). In November 2025 the FDA began removing the boxed warnings about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels, and it approved the first updated labels in February 2026. The boxed warning about endometrial cancer stays on systemic estrogen-alone products, because women with a uterus still need a progestogen.

Breast Cancer Risk: The Nuances

The breast cancer question is the most common concern women raise. Here is what the evidence shows:

• Estrogen-only therapy (for women without a uterus) was associated with a decreased risk of breast cancer in the WHI, even after 20 years of follow-up (Chlebowski et al., 2020).
• Combined estrogen-progestogen therapy was associated with a small increased risk, appearing after approximately 3 to 5 years of use.
• The type of progestogen matters. Micronized progesterone and dydrogesterone appear to carry less risk than synthetic progestins like MPA (Fournier et al., 2008).
• To put the risk in perspective, the increase is similar to the breast cancer risk associated with drinking one to two glasses of wine per day, being obese, or being sedentary.

The 20-year WHI follow-up by Chlebowski and colleagues was published in JAMA (Chlebowski et al., JAMA, 2020). The French E3N cohort, which followed more than 80,000 women, found no clear rise in breast cancer with estrogen plus micronized progesterone over the follow-up period studied (Fournier et al., Breast Cancer Res Treat, 2008).

Blood Clot Risk

Oral estrogen increases the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) because of its effect on liver clotting factor production. Transdermal estrogen does not carry this increased risk, which is why most menopause specialists now prefer patches, gels, or sprays, especially for women with additional clot risk factors (obesity, smoking, thrombophilia) (Mohammed et al., 2015).

Stroke Risk

There is a small increased risk of ischemic stroke with oral HRT, particularly at higher doses. Again, transdermal delivery and lower doses appear to mitigate this risk. For women under 60, the absolute risk is very low.

HRT risks and benefits at a glance

The size of each risk depends on the hormone, the route and the age at which HRT starts. The table summarizes the findings already described in the benefits and risks sections.

Common HRT Side Effects

The most common HRT side effects are breast tenderness, bloating, headaches, nausea and irregular bleeding or spotting, and most settle within the first 3 months as the dose is adjusted. Progesterone can cause drowsiness, which is why micronized progesterone is usually taken at bedtime. Patches can irritate the skin where they sit.

Side effects that need prompt attention include calf pain or swelling, chest pain or sudden breathlessness, a new severe headache, vision changes, a breast lump, and heavy or persistent bleeding after the first few months. The dedicated guide to HRT side effects lists each one with the usual fix, such as changing the route, the progestogen or the dose.

Testosterone for Women

Testosterone is not just a “male hormone.” Women produce testosterone in their ovaries and adrenal glands, and levels decline with age. After menopause, testosterone levels are roughly half of what they were at age 20.

The most well-supported indication for testosterone therapy in women is hypoactive sexual desire disorder (HSDD), basically low libido that causes distress. A 2019 global consensus statement concluded that testosterone at physiological doses can improve sexual desire, arousal, orgasm, and satisfaction in postmenopausal women (Davis et al., 2019).

That Global Consensus Position Statement, led by Susan Davis and endorsed by societies including the Endocrine Society and the International Menopause Society, was published in the Journal of Clinical Endocrinology and Metabolism (Davis et al., J Clin Endocrinol Metab, 2019). It found too little evidence to recommend testosterone for mood, energy, bone or cognition. The guide to low libido in women covers the other causes worth ruling out first.

Some practitioners also prescribe testosterone for energy, mood, cognitive sharpness, and muscle maintenance, though the evidence for these indications is less established. No testosterone product is currently FDA-approved for women, so prescriptions are typically compounded or involve off-label use of low-dose male formulations.

Side effects at appropriate doses are uncommon but can include acne, facial hair growth, and voice deepening if levels go too high. Monitoring with blood tests is important to keep levels within the physiological female range.

DHEA (dehydroepiandrosterone) is another androgen precursor sometimes prescribed alongside or instead of testosterone. An intravaginal DHEA product (Intrarosa/prasterone) is FDA-approved for treating painful intercourse due to menopause. Oral DHEA supplements are available over the counter, though their efficacy and safety for menopause symptoms are not well established in clinical trials.

Starting HRT: What to Expect

If you and your provider decide HRT is right for you, here is a realistic timeline of what to expect. Most women notice improvement in vasomotor symptoms (hot flashes, night sweats) within the first 2 to 4 weeks, though full benefit may take up to 3 months. Vaginal dryness and urinary symptoms improve more slowly, sometimes taking 3 to 6 months of consistent local estrogen use.

Sleep quality often improves early, partly because night sweats diminish. Mood stabilization can take several weeks. Some women experience breast tenderness, bloating, or irregular bleeding during the first 1 to 3 months as the body adjusts. These side effects typically resolve on their own. If they persist, your provider may adjust the dose or formulation.

It is common to need dose adjustments in the first 6 months. This is normal and not a sign that something is wrong. Your provider should schedule a follow-up visit within 2 to 3 months of starting therapy to review symptom response and address any concerns.

How to prepare for your first HRT appointment

1. Write down your symptoms, how often they happen and how much they affect sleep and work.
2. Note the date of your last period and any bleeding since then.
3. Gather your history of blood clots, migraine, breast or uterine cancer, heart disease and liver disease, including close relatives.
4. Bring the date of your last mammogram and cervical screening.
5. Decide which delivery method you would prefer to try first, and ask what the plan is if the first dose does not help.

Monitoring and Lab Work

Once you start HRT, regular follow-up is important. Here is what most menopause specialists will monitor:

• Symptom check: Are your hot flashes, sleep, mood, and vaginal symptoms improving? Symptom response is the primary guide to dosing.
• Estradiol levels: Useful for ensuring adequate absorption, particularly with transdermal delivery. Target ranges vary but typically aim for 40 to 100 pg/mL for symptom relief.
• FSH: Less useful for dose adjustment once on HRT, but helpful in confirming menopause status before starting therapy.
• Testosterone levels: If supplementing testosterone, free and total testosterone should be checked to avoid supraphysiological levels.
• Lipid panel and metabolic markers: HRT can affect lipids (generally favorably with transdermal estrogen).
• Mammograms and breast exams: Continue routine screening. HRT, especially combined therapy, can increase breast density, which may require additional imaging.
• Endometrial monitoring: Any unexpected bleeding on HRT should be evaluated with ultrasound and possibly biopsy.

Routine hormone panels are not required for most women on standard FDA-approved doses, because symptom response guides the dose. Blood tests matter most when symptoms persist on a transdermal product, when testosterone is added, or when a compounded product makes the delivered dose uncertain.

How Long Should You Stay on HRT?

The old advice of “lowest dose for the shortest time” was born out of post-WHI anxiety and is increasingly being questioned. Here is a more contemporary perspective:

There is no arbitrary time limit on HRT. The decision to continue should be individualized and revisited annually. For women who started HRT for vasomotor symptoms, many find that symptoms persist for 7 to 10 years or longer. Stopping HRT just because five years have passed makes little sense if symptoms return.

For women with premature ovarian insufficiency, HRT should continue at minimum until the average age of natural menopause (51) and often beyond. For bone protection, HRT benefits last only as long as treatment continues. The 2022 Menopause Society position statement supports continued use when benefits outweigh risks for the individual patient (The Menopause Society, 2022).

The FDA reached the same view in its November 2025 labeling change request, which asked manufacturers to drop the recommendation to use the lowest effective dose for the shortest time. Continuing past age 60 or 65 is a reasonable choice for many women, with a yearly review of symptoms, bone health and personal risk factors.

Coming Off HRT

If you and your provider decide it is time to stop HRT, gradual tapering is generally preferred over abrupt discontinuation. A common approach is to reduce the dose by one step every 2 to 3 months. This minimizes the likelihood of symptom rebound.

Be aware that some women find symptoms return when they try to stop, even after years of therapy. This is not a sign of dependence. It is a sign that your body still has a significant hormone deficit. In these cases, continuing low-dose therapy or switching to vaginal estrogen alone for GSM symptoms is a reasonable option.

Bone protection fades after HRT stops, so women with low bone density usually move to another bone treatment, such as a bisphosphonate, with a bone density (DEXA) scan to guide the choice.

Non-Hormonal Alternatives to HRT

Women who cannot or prefer not to take hormones have several prescription options for hot flashes. Fezolinetant (Veozah), approved by the FDA in 2023, blocks the neurokinin 3 receptor in the brain's temperature center. Low-dose paroxetine is FDA-approved for hot flashes, and other SSRIs and SNRIs, gabapentin and oxybutynin are used off label.

The Menopause Society's 2023 nonhormone therapy position statement also supports cognitive behavioral therapy (CBT), clinical hypnosis and weight loss for hot flashes. It does not recommend most supplements, including black cohosh and soy isoflavones, because trials show little benefit over placebo. None of these options protects bone the way estrogen does. The menopause treatment guide compares hormonal and non-hormonal approaches side by side.

How Much Does HRT Cost and Is It Covered by Insurance?

FDA-approved HRT, including generic estradiol patches, gels and tablets and micronized progesterone, is usually covered by commercial insurance and Medicare Part D prescription plans, subject to each plan's formulary and copays. Coverage varies by plan, so checking the formulary for the exact product before the first fill saves surprises.

Compounded BHRT, hormone pellets and testosterone for women are usually paid out of pocket, because they are not FDA-approved for these uses. Clinics that offer them often bundle visits, lab work and the hormones into a membership or package, so ask for an itemized quote and what happens if you stop early.

Finding a Menopause Specialist

One of the biggest barriers to good HRT care is provider knowledge. Studies show that many primary care physicians and even OB-GYNs receive minimal training in menopause management. A 2013 survey found that only 20% of OB-GYN residency programs had a formal menopause curriculum (Christianson et al., 2013).

That survey of American obstetrics and gynecology residents, by Christianson and colleagues at Johns Hopkins, was published in the journal Menopause (Christianson et al., Menopause, 2013). The gap is one reason many women see more than one clinician before getting a clear answer.

If your provider is uncomfortable prescribing HRT or relies on outdated WHI-era fears, seek a specialist. Look for:

• NAMS-certified menopause practitioners (NCMP): The North American Menopause Society certifies providers who have passed a competency exam. Search their directory at menopause.org.
• Reproductive endocrinologists with menopause expertise.
• Endocrinologists who specialize in female hormones.
• Telemedicine menopause clinics have expanded access significantly in recent years. Several platforms now specialize in evidence-based menopause care.

Gynecologists, family physicians, internists, nurse practitioners and physician assistants can all prescribe HRT. The menopause specialist guide explains the credentials and what a first visit with each type of clinician covers.

Using the Regenerated.com directory to compare HRT clinics

The national directory of hormone replacement therapy clinics lists menopause, hormone and functional medicine practices by state and city. Listing order is not a paid ranking. Featured slots are clearly labeled and capped, Verified means the clinic passed credential checks rather than paying for placement, and the directory is free for patients to use. Inclusion in the list is not an endorsement, and the guide to Featured, Verified and organic listings explains each label.

Before booking, ask each clinic whether it prescribes FDA-approved estradiol and progesterone, who writes the prescription, how often it checks in during the first 6 months and whether it bills insurance. The HRT treatment overview sets out the basics to compare clinics against.

Frequently Asked Questions

Is HRT safe if I have a family history of breast cancer?

A family history of breast cancer is not an automatic contraindication to HRT. The decision depends on which relative was affected, at what age, whether BRCA1/2 genetic testing has been done, and how severe your symptoms are. Estrogen-only therapy, for women without a uterus, does not appear to increase breast cancer risk, and transdermal estrogen with micronized progesterone is the usual combined choice. Discuss your individual risk with a breast oncologist or menopause specialist before starting.

Will HRT cause weight gain?

No. Menopause itself is associated with changes in body composition, with more abdominal fat and less muscle mass, but randomized trials show HRT does not cause weight gain and may help prevent the shift to central adiposity (Davis et al., 2012). Some women notice bloating or fluid retention in the first months, which usually settles. Diet, strength training and sleep matter more for menopausal weight than hormone therapy does.

Can I take HRT if I have migraines?

Yes, many women with migraines can take HRT, but the route matters. Migraines with aura are a risk factor for stroke, and oral estrogen may add to that risk. Transdermal estrogen at a steady dose, which avoids the hormone swings that trigger attacks, is generally considered the safer option. Your provider should assess your migraine type, how often attacks occur and other stroke risk factors such as smoking and high blood pressure before choosing a dose.

What about “natural” alternatives to HRT?

Phytoestrogens (soy isoflavones), black cohosh, and other supplements have been studied, and the evidence for most is weak to modest. Some women get mild relief, but none matches the efficacy of HRT for moderate to severe symptoms. CBT and clinical hypnosis have some evidence for hot flash management. If you cannot or choose not to take HRT, non-hormonal prescription options like fezolinetant (Veozah) and SSRIs/SNRIs can help (Johnson et al., 2023).

How long does it take for HRT to start working?

Most women notice fewer hot flashes and night sweats within 2 to 4 weeks of starting systemic HRT, with full benefit by about 3 months. Sleep often improves early because night sweats ease. Vaginal dryness and urinary symptoms respond more slowly, often over 3 to 6 months of regular vaginal estrogen. If symptoms have not improved after 3 months, the usual next step is a dose or route change rather than stopping treatment.

Is it too late to start HRT after 60?

Starting HRT after 60, or more than 10 years after the last period, is not ruled out, but the balance of benefit and risk is less favorable. The WHI and ELITE data show higher rates of heart disease, stroke and clots when systemic HRT starts late. For bothersome symptoms, specialists may still offer low-dose transdermal estrogen after a careful risk review. Vaginal estrogen for dryness and urinary symptoms can be started at any age.

The Bottom Line

HRT has been through decades of controversy, but the science has matured considerably. For the right woman, at the right time, with the right formulation, it remains the gold standard for menopause symptom management and offers meaningful benefits for bone, heart, and possibly brain health.

The key is individualized care from a knowledgeable provider who understands the nuances. Do not let fear from outdated headlines keep you from a treatment that could significantly improve your quality of life during menopause and beyond.

In practical terms, hormone replacement therapy relieves hot flashes and night sweats more than any other treatment, protects bone while it is taken, and carries the lowest risk when started before 60 or within 10 years of menopause, using transdermal estradiol and micronized progesterone where possible.

Sources

1. Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015;44(3):497-515. PubMed
2. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647-1657. PubMed
3. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753. PubMed
4. Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs Transdermal Estrogen Therapy and Vascular Events. J Clin Endocrinol Metab. 2015;100(11):4012-4020. PubMed
5. The North American Menopause Society. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer. Menopause. 2020;27(12):1397-1402. PubMed
6. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies. Breast Cancer Res Treat. 2008;107(1):103-111. PubMed
7. Endocrine Society. Testosterone Therapy in Women: A Clinical Practice Guideline. J Clin Endocrinol Metab. 2016. PubMed
8. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978. PubMed
9. Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-937. PubMed
10. Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE). N Engl J Med. 2016;374(13):1221-1231. PubMed
11. Henderson VW, Brinton RD. Menopause and Mitochondria: Windows into Estrogen Effects on Alzheimer’s Disease Risk and Therapy. Prog Brain Res. 2021;182:77-96. PubMed
12. Writing Group for the Women’s Health Initiative. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. JAMA. 2002;288(3):321-333. PubMed
13. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the WHI Randomized Clinical Trials. JAMA. 2020;324(4):369-380. PubMed
14. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PubMed
15. Christianson MS, Ducie JA, Engber K, et al. Menopause education: needs assessment of American obstetrics and gynecology residents. Menopause. 2013;20(11):1120-1125. PubMed
16. Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric. 2012;15(5):419-429. PubMed
17. Johnson KA, Martin N, Nappi RE, et al. Efficacy and Safety of Fezolinetant for Moderate to Severe Vasomotor Symptoms. J Clin Endocrinol Metab. 2023. PubMed
18. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
19. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. PubMed
20. Writing Group for the Women’s Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy (Anderson GL, et al.). JAMA. 2004;291(14):1701-1712. PubMed
21. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477. PubMed
22. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
23. U.S. Food and Drug Administration. FDA requests labeling changes related to safety information to clarify the benefit/risk considerations for menopausal hormone therapies. November 10, 2025. FDA

Related Reading

• Shockwave Therapy: A Complete Evidence-Based Guide
• Peptide Therapy: What the Evidence Says
• Red Light Therapy: Benefits, Evidence, and How to Use It
• Functional Medicine: What It Is and What to Expect
• Menopause Guide: Stages and Symptoms
• HRT for Women